Platform trials - Revision history

Lawrence: /* Conclusion */

2025-06-04T13:20:41Z

Conclusion

← Older revision		Revision as of 13:20, 4 June 2025
Line 13:		Line 13:
	A shared control group is used across all intervention arms, which reduces the number of participants needed for control comparisons. This setup improves statistical power and streamlines recruitment.		A shared control group is used across all intervention arms, which reduces the number of participants needed for control comparisons. This setup improves statistical power and streamlines recruitment.

	These trials typically rely on advanced statistical models, including Bayesian or frequentist adaptive methods. These models help guide adaptive randomization and decision-making during interim analyses.		These trials typically rely on advanced statistical models, including Bayesian or frequentist adaptive methods. These models help guide adaptive [[randomization]] and decision-making during interim analyses.

	Unlike conventional trials that end after evaluating one treatment, platform trials are designed to remain open and flexible over time. This allows them to respond to emerging health challenges or new research questions.		Unlike conventional trials that end after evaluating one treatment, platform trials are designed to remain open and flexible over time. This allows them to respond to emerging health challenges or new research questions.
Line 31:		Line 31:
	Despite their benefits, platform trials present several challenges. Designing and managing such trials requires considerable statistical and operational sophistication.		Despite their benefits, platform trials present several challenges. Designing and managing such trials requires considerable statistical and operational sophistication.

	The complexity of the trial design often demands advanced statistical methods to ensure valid comparisons and control for multiple testing. Adaptive randomization must be carefully pre-specified and rigorously implemented to maintain trial integrity.		The complexity of the trial design often demands advanced statistical methods to ensure valid comparisons and control for [[multiple testing]]. Adaptive randomization must be carefully pre-specified and rigorously implemented to maintain trial integrity.

	From a regulatory standpoint, frequent protocol amendments—for example, to add or drop trial arms—can complicate interactions with ethics committees and regulatory agencies. Clear, pre-defined decision rules are essential to gain and maintain regulatory approval.		From a regulatory standpoint, frequent protocol amendments—for example, to add or drop trial arms—can complicate interactions with [[ethics]] committees and regulatory agencies. Clear, pre-defined decision rules are essential to gain and maintain regulatory approval.

	Ethical considerations are also important. Informed consent documents must clearly explain the adaptive nature of the trial, including the possibility that treatment arms may change during the study. Participants should understand that they may be allocated to a newly introduced treatment mid-trial.		Ethical considerations are also important. [[Informed consent]] documents must clearly explain the adaptive nature of the trial, including the possibility that treatment arms may change during the study. Participants should understand that they may be allocated to a newly introduced treatment mid-trial.

	Operationally, platform trials require robust data systems and real-time monitoring to enable timely interim analyses and adaptive decision-making. Trial teams must manage complex logistics, including coordinating multiple arms, managing eligibility criteria, and implementing adaptive changes.		Operationally, platform trials require robust data systems and real-time monitoring to enable timely interim analyses and adaptive decision-making. Trial teams must manage complex logistics, including coordinating multiple arms, managing eligibility criteria, and implementing adaptive changes.
Line 70:		Line 70:
	Platform trials are a powerful innovation in clinical trial methodology. By allowing for the evaluation of multiple treatments over time using a shared infrastructure, they improve efficiency, accelerate evidence generation, and make better use of limited resources.		Platform trials are a powerful innovation in clinical trial methodology. By allowing for the evaluation of multiple treatments over time using a shared infrastructure, they improve efficiency, accelerate evidence generation, and make better use of limited resources.

	They are particularly useful in areas where timely answers are critical, such as public health emergencies or rapidly evolving diseases. However, their complexity requires careful planning, sophisticated analysis, and strong coordination to ensure valid and ethical results.		They are particularly useful in areas where timely answers are critical, such as public health emergencies or rapidly evolving diseases. However, their complexity requires careful planning, sophisticated [[analysis]], and strong coordination to ensure valid and ethical results.

	----		----

	~~See also~~:		=== Bibliography ===
	* [[~~Adaptive Trial Designs~~]]
	* [[Multi-Arm Trials]]		# Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. ''New England Journal of Medicine''. 2017;377(1):62–70.
	* [[Bayesian Methods in Trials]]		# Park JJH, Siden E, Zoratti MJ, et al. [[Systematic review]] of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. ''Trials''. 2019;20:572.
	* [[CONSORT]]		# Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. ''Nature Reviews Drug Discovery''. 2019;18(10):797–807.
			# Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. ''Clinical Trials''. 2016;13(3):358–366.
			# Angus DC, Alexander BM, Berry S, et al. Adaptive platform trials: definition, design, conduct and reporting considerations. ''Nature Reviews Drug Discovery''. 2023;22(5):337–348.

			----
			''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence: Created page with "= Platform trials = A '''platform trial''' is a type of adaptive clinical trial that enables the evaluation of multiple treatments within a single, continuous trial structure. Unlike traditional randomized controlled trials (RCTs), which compare one treatment against a control, platform trials are designed to simultaneously test several interventions using a shared control group and a common protocol. Treatments can be added or dropped from the trial as new evidence bec..."

2025-03-26T18:06:36Z

Created page with "= Platform trials = A '''platform trial''' is a type of adaptive clinical trial that enables the evaluation of multiple treatments within a single, continuous trial structure. Unlike traditional randomized controlled trials (RCTs), which compare one treatment against a control, platform trials are designed to simultaneously test several interventions using a shared control group and a common protocol. Treatments can be added or dropped from the trial as new evidence bec..."

New page

= Platform trials =

A '''platform trial''' is a type of adaptive clinical trial that enables the evaluation of multiple treatments within a single, continuous trial structure. Unlike traditional randomized controlled trials (RCTs), which compare one treatment against a control, platform trials are designed to simultaneously test several interventions using a shared control group and a common protocol. Treatments can be added or dropped from the trial as new evidence becomes available.

This design has gained increasing popularity in fields such as oncology, infectious diseases, and precision medicine. High-profile examples include the [[RECOVERY]] trial for COVID-19 treatments and the I-SPY 2 trial for breast cancer.

== Key Features ==

One defining characteristic of platform trials is the ability to evaluate multiple treatments at once. For instance, several experimental drugs may be tested against a common control arm within the same trial. This design allows for more efficient use of resources and quicker comparative insights across arms.

Platform trials also use an adaptive structure, meaning that interventions can be added or removed over time. If interim analyses show that a treatment is ineffective or unsafe, it can be discontinued early. Conversely, new interventions can be introduced into the trial framework without starting a new trial from scratch.

A shared control group is used across all intervention arms, which reduces the number of participants needed for control comparisons. This setup improves statistical power and streamlines recruitment.

These trials typically rely on advanced statistical models, including Bayesian or frequentist adaptive methods. These models help guide adaptive randomization and decision-making during interim analyses.

Unlike conventional trials that end after evaluating one treatment, platform trials are designed to remain open and flexible over time. This allows them to respond to emerging health challenges or new research questions.

== Advantages ==

Platform trials offer several practical and scientific advantages. First, they increase efficiency by enabling multiple interventions to be tested in parallel. This can significantly reduce the time and cost associated with running separate trials.

Second, the use of interim analyses allows for faster decision-making. Ineffective interventions can be dropped early, and promising ones can proceed more rapidly through the research pipeline.

Third, by using a shared control group, platform trials reduce the number of participants needed, particularly in the control arm. This not only conserves resources but may also enhance ethical acceptability by minimizing the number of participants not receiving an experimental treatment.

In times of urgent need—such as a pandemic—platform trials offer real-time flexibility to evaluate treatments quickly. Their design is especially well suited for rapidly evolving conditions and complex diseases.

== Challenges and Considerations ==

Despite their benefits, platform trials present several challenges. Designing and managing such trials requires considerable statistical and operational sophistication.

The complexity of the trial design often demands advanced statistical methods to ensure valid comparisons and control for multiple testing. Adaptive randomization must be carefully pre-specified and rigorously implemented to maintain trial integrity.

From a regulatory standpoint, frequent protocol amendments—for example, to add or drop trial arms—can complicate interactions with ethics committees and regulatory agencies. Clear, pre-defined decision rules are essential to gain and maintain regulatory approval.

Ethical considerations are also important. Informed consent documents must clearly explain the adaptive nature of the trial, including the possibility that treatment arms may change during the study. Participants should understand that they may be allocated to a newly introduced treatment mid-trial.

Operationally, platform trials require robust data systems and real-time monitoring to enable timely interim analyses and adaptive decision-making. Trial teams must manage complex logistics, including coordinating multiple arms, managing eligibility criteria, and implementing adaptive changes.

== Comparison with Other Trial Types ==

The following table outlines how platform trials differ from other innovative trial designs:

{| class="wikitable" style="width:100%;"
! Trial Type !! Key Characteristics !! Example
|-
| Traditional RCT || One treatment vs. control; fixed design || PARADIGM-HF (heart failure)
|-
| Basket Trial || One treatment tested across multiple diseases || NCI-MATCH (cancer genomics)
|-
| Umbrella Trial || Multiple treatments tested in one disease || I-SPY 2 (breast cancer)
|-
| Platform Trial || Multiple treatments; adaptive design; shared control || RECOVERY (COVID-19)
|}

== Examples of Platform Trials ==

'''RECOVERY Trial (UK, COVID-19):'''
A large-scale platform trial that evaluated multiple treatments for hospitalized COVID-19 patients, including dexamethasone and hydroxychloroquine. It used a shared control group and adaptive protocol to add or drop interventions based on real-time data.

'''I-SPY 2 Trial (USA, Breast Cancer):'''
An adaptive platform trial using Bayesian randomization to test multiple investigational drugs for breast cancer. New treatments are added dynamically based on early results from specific patient subtypes.

'''REMAP-CAP Trial (Global, Critical Care):'''
A platform trial investigating treatments for critically ill patients with pneumonia and COVID-19. It uses a Bayesian adaptive framework to compare multiple treatments across domains like antivirals, immunomodulators, and anticoagulants.

== Conclusion ==

Platform trials are a powerful innovation in clinical trial methodology. By allowing for the evaluation of multiple treatments over time using a shared infrastructure, they improve efficiency, accelerate evidence generation, and make better use of limited resources.

They are particularly useful in areas where timely answers are critical, such as public health emergencies or rapidly evolving diseases. However, their complexity requires careful planning, sophisticated analysis, and strong coordination to ensure valid and ethical results.

----

See also:
* [[Adaptive Trial Designs]]
* [[Multi-Arm Trials]]
* [[Bayesian Methods in Trials]]
* [[CONSORT]]